PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.

Abstract The mechanism of the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance included T790M mutation, cellular-mesenchymal to epithelial transition factor (MET) or EGFR amplification, PIK3CA mutation, and transformation to small cell lung cancer. MET amplification accounted for only about 5% of the resistance cases.
PMID
Related Publications

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29505507
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20180309
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 1
DP  - 2018 Jan
TI  - Effective assessment of low times MET amplification in pleural effusion after
      epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired 
      resistance: Cases report.
PG  - e9021
LID - 10.1097/MD.0000000000009021 [doi]
AB  - RATIONALE: The mechanism of the first-generation epidermal growth factor
      receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance included
      T790M mutation, cellular-mesenchymal to epithelial transition factor (MET) or
      EGFR amplification, PIK3CA mutation, and transformation to small cell lung
      cancer. MET amplification accounted for only about 5% of the resistance cases.
      PATIENTS CONCERNS: Few report detected MET amplification in pleural effusion.
      Here, we reported 2 lung adenocarcinoma cases with MET amplification in pleural
      effusion rapidly responded to crizotinib after EGFR-TKIs acquired resistance.
      DIAGNOSES: Biopsy via bronchoscopy, next-generation sequencing (NGS) in pleural
      effusion. INTERVENTIONS: EGFR-TKIs (Icotinib), MET inhibitor crizotinib.
      OUTCOMES: After a progression-free survival of 9 months and 23months,
      respectively, both cases progressed accompanying with pleural effusion. Results
      of NGS in pleural effusion showed MET amplification (2-3 times) in both cases.
      The 2 patients were treated with a MET inhibitor crizotinib and rapidly
      responded. CONCLUSION: MET amplification in pleural effusion could predict a
      perfect response to crizotinib after EGFR-TKIs acquired resistance, even only a
      low times gene amplification.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Wang, Chang-Guo
AU  - Wang CG
AD  - Department of Respiratory and Critical Care, First Affiliated Hospital of Soochow
      University, Suzhou, P.R. China.
FAU - Zeng, Da-Xiong
AU  - Zeng DX
FAU - Huang, Jian-An
AU  - Huang JA
FAU - Jiang, Jun-Hong
AU  - Jiang JH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (crizotinib)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - AIM
SB  - IM
MH  - Adenocarcinoma/drug therapy/*genetics
MH  - Aged
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Pleural Effusion, Malignant/*metabolism
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins c-met/*genetics/metabolism
MH  - Pyrazoles/therapeutic use
MH  - Pyridines/therapeutic use
EDAT- 2018/03/06 06:00
MHDA- 2018/03/10 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
AID - 10.1097/MD.0000000000009021 [doi]
AID - 00005792-201801050-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jan;97(1):e9021. doi: 10.1097/MD.0000000000009021.